Nxera Pharma Co., Ltd.
4565.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -¥1,672,000 | -¥2,377,000 | -¥760,000 | -¥1,335,000 |
| Dep. & Amort. | ¥1,106,000 | ¥1,095,000 | ¥1,082,000 | ¥1,003,000 |
| Deferred Tax | ¥0 | ¥0 | ¥0 | ¥0 |
| Stock-Based Comp. | ¥0 | ¥0 | ¥0 | ¥371,000 |
| Change in WC | -¥1,173,000 | -¥915,000 | ¥324,000 | -¥7,228,000 |
| Other Non-Cash | -¥1,237,000 | ¥2,017,000 | -¥33,000 | -¥3,781,000 |
| Operating Cash Flow | -¥2,976,000 | -¥180,000 | ¥613,000 | -¥10,970,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -¥105,000 | -¥90,000 | -¥262,000 | -¥153,000 |
| Net Acquisitions | ¥0 | ¥0 | ¥0 | ¥0 |
| Inv. Purchases | ¥0 | ¥0 | ¥0 | ¥0 |
| Inv. Sales/Matur. | ¥43,000 | ¥9,000 | ¥3,841,000 | ¥0 |
| Other Inv. Act. | ¥13,000 | -¥1,000 | ¥18,000 | -¥4,791,000 |
| Investing Cash Flow | -¥49,000 | -¥82,000 | ¥3,597,000 | -¥4,944,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -¥1,450,000 | -¥1,450,000 | -¥1,450,000 | -¥1,300,000 |
| Stock Issued | ¥0 | ¥0 | ¥0 | ¥0 |
| Stock Repurch. | ¥0 | ¥0 | ¥0 | ¥0 |
| Dividends Paid | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Fin. Act. | -¥224,000 | -¥227,000 | -¥223,000 | -¥374,000 |
| Financing Cash Flow | -¥1,674,000 | -¥1,677,000 | -¥1,673,000 | -¥1,674,000 |
| Forex Effect | ¥163,000 | ¥471,000 | -¥340,000 | ¥988,000 |
| Net Chg. in Cash | -¥4,536,000 | -¥1,468,000 | ¥2,197,000 | -¥16,600,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | ¥32,997,000 | ¥34,465,000 | ¥32,268,000 | ¥48,868,000 |
| End Cash | ¥28,461,000 | ¥32,997,000 | ¥34,465,000 | ¥32,268,000 |
| Free Cash Flow | -¥3,078,000 | -¥270,000 | ¥504,000 | -¥11,123,000 |